Article

Risk of death due to heart and vascular disease higher in black patients with glaucoma

According to the Barbados Eye Studies, black people treated for glaucoma are at increased risk of dying from heart and vascular disease, particularly those treated with timolol maleate eye drops.

New York-According to the Barbados Eye Studies, black people treated for glaucoma are at increased risk of dying from heart and vascular disease, particularly those treated with timolol maleate eye drops.

"Glaucoma is one of the leading causes of visual impairment worldwide," Suh-Yuh Wu and colleagues noted in the Archives of Ophthalmology. "The most common type, primary open-angle glaucoma, is especially prevalent in populations of African origin, in which it is the foremost cause of blindness."

More than 90% of the Barbados population is black, life expectancy is high, and health care is free. The study evaluated long-term mortality rates among 4,092 subjects who had eye examinations between 1987 and 1992.

At the start of the study, 300 participants had glaucoma, including 141 who had been diagnosed and treated. After 9 years, 764 of the participants had died. The risk of death from cardiovascular causes was 38% higher in people who had previously been diagnosed with or treated for open-angle glaucoma and 91% higher in those who had been treated with timolol drops.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.